Reig Jofre, a CataloniaBio & HealthTech member, is the force behind a clinical study to evaluate the efficacy of the Manremyc® in 300 health professionals exposed to the risk of contracting Covid-19.
Manremyc® is an oral food supplement based on heatinactivated Mycobacterium s. manresensis bacilli for tuberculosis, result of the research over more than 10 years by the Experimental Tuberculosis Unit of the Germans Trias i Pujol Research Institute (IGTP).
The study will be carried out in coordination with the IGTP together with the Institute for Research in Primary Care Jordi Gol, and led by Dr Pere-Joan Cardona.
The pharmaceutical company expects to obtain the results in October 2020. In the event of Manremyc® proving effective against Covid-19, it could be supplied for general use very easily (1 capsule per day for only 14 days) and its high tolerability.
On the other hand, Reig Jofre closed the first quarter of 2020 with a growth of 26% in sales.
Comments